24-NHL-39-FTI-PMC(FT522-101): A Phase 1 Study of FT522 in Combination with Rituximab in Participants with Relapsed/Refractory B-Cell Lymphoma

Grants and Contracts Details

StatusActive
Effective start/end date10/28/24 → 10/28/26

Funding

  • Fate Therapeutics Incorporated: $2.00